Market Closed -
Canadian Securities Exchange
07:00:00 26/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
0.035
CAD
|
+16.67%
|
|
0.00%
|
0.00%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
133.8
|
122.5
|
39.05
|
4.678
|
7.97
|
Enterprise Value (EV)
1 |
118.9
|
124.3
|
36.22
|
17.68
|
32.78
|
P/E ratio
|
-0.55
x
|
-7.32
x
|
-0.64
x
|
-0.13
x
|
-0.35
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.14
x
|
5.31
x
|
1.05
x
|
0.12
x
|
0.23
x
|
EV / Revenue
|
4.57
x
|
5.39
x
|
0.97
x
|
0.47
x
|
0.93
x
|
EV / EBITDA
|
-3.12
x
|
-5.99
x
|
-2.07
x
|
-1.64
x
|
-7.66
x
|
EV / FCF
|
1.77
x
|
-9.5
x
|
-2.81
x
|
8.56
x
|
-2.7
x
|
FCF Yield
|
56.6%
|
-10.5%
|
-35.6%
|
11.7%
|
-37%
|
Price to Book
|
3.29
x
|
1.84
x
|
1.02
x
|
0.38
x
|
-1.82
x
|
Nbr of stocks (in thousands)
|
46,941
|
63,791
|
92,981
|
1,16,959
|
2,27,712
|
Reference price
2 |
2.850
|
1.920
|
0.4200
|
0.0400
|
0.0350
|
Announcement Date
|
26/05/20
|
29/04/21
|
28/04/22
|
27/04/23
|
12/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
4.774
|
26
|
23.08
|
37.27
|
37.93
|
35.34
|
EBITDA
1 |
-14.9
|
-38.13
|
-20.76
|
-17.52
|
-10.78
|
-4.282
|
EBIT
1 |
-14.98
|
-59.16
|
-25.53
|
-23.45
|
-15.15
|
-6.327
|
Operating Margin
|
-313.65%
|
-227.52%
|
-110.6%
|
-62.91%
|
-39.94%
|
-17.9%
|
Earnings before Tax (EBT)
1 |
-28.28
|
-234.8
|
-16.7
|
-51.86
|
-29.46
|
-17.77
|
Net income
1 |
-28.28
|
-200.3
|
-14.06
|
-56.09
|
-30.27
|
-19.37
|
Net margin
|
-592.29%
|
-770.41%
|
-60.92%
|
-150.47%
|
-79.81%
|
-54.8%
|
EPS
2 |
-2.220
|
-5.220
|
-0.2623
|
-0.6603
|
-0.2992
|
-0.1011
|
Free Cash Flow
1 |
-66.52
|
67.25
|
-13.09
|
-12.9
|
2.067
|
-12.12
|
FCF margin
|
-1,393.22%
|
258.61%
|
-56.71%
|
-34.6%
|
5.45%
|
-34.3%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/04/19
|
26/05/20
|
29/04/21
|
28/04/22
|
27/04/23
|
12/04/24
|
Fiscal Period: December |
2022 Q2
|
---|
Net sales
|
-
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
|
-
|
Net margin
|
-
|
EPS
1 |
-0.0300
|
Dividend per Share
|
-
|
Announcement Date
|
25/08/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
2.58
|
-
|
1.87
|
-
|
13
|
24.8
|
Net Cash position
1 |
-
|
14.9
|
-
|
2.84
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.173
x
|
-
|
-0.0898
x
|
-
|
-1.207
x
|
-5.794
x
|
Free Cash Flow
1 |
-66.5
|
67.2
|
-13.1
|
-12.9
|
2.07
|
-12.1
|
ROE (net income / shareholders' equity)
|
-85%
|
-377%
|
-26.2%
|
-97.8%
|
-116%
|
-478%
|
ROA (Net income/ Total Assets)
|
-20.2%
|
-38.5%
|
-15.3%
|
-15.7%
|
-15.5%
|
-10.4%
|
Assets
1 |
139.7
|
520.4
|
91.85
|
357.6
|
195.1
|
186
|
Book Value Per Share
2 |
4.260
|
0.8700
|
1.050
|
0.4100
|
0.1100
|
-0.0200
|
Cash Flow per Share
2 |
0.0100
|
0.1800
|
0.1000
|
0.1800
|
0.0700
|
0.0200
|
Capex
1 |
0.18
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
3.74%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/04/19
|
26/05/20
|
29/04/21
|
28/04/22
|
27/04/23
|
12/04/24
|
|
1st Jan change
|
Capi.
|
---|
| 0.00% | 5.82M | | +31.96% | 272M | | +33.74% | 261M | | +49.42% | 194M | | +44.98% | 131M | | -42.17% | 119M | | -28.57% | 121M | | +115.91% | 119M | | 0.00% | 86.82M | | +150.00% | 75.33M |
Medical Farming
|